Registreer u om meldingen in te stellen voor instrumenten, economische gebeurtenissen en artikelen van de auteurs die u volgt.
Gratis registreren Heeft u al een account? Inloggen
Noteringen
Alle soorten instrumenten
- Alle soorten instrumenten
- Indexen
- Aandelen
- ETF's
- Fondsen
- Grondst.
- Valuta's
- Crypto
- Obligaties
- Certificaten
Probeer een andere zoekopdracht
Nieuw! 💥 Krijg ProPicks om te zien welke strategie de S&P 500 met 1,183% heeft overtroffen KORTING van 40% benutten
Axa Framlington Biotech Fund - R Accumulation (0P0000XMRD)
Toevoegen/Verwijderen van een Portfolio
Voeg toe aan Portfolio
5,177
+0,040
+0,82%
Type:
Fonds
Markt:
Verenigd Koninkrijk
Emittent:
AXA Equitable
ISIN:
GB00B784NS11
Activaklasse:
Aandeel
- Beoordeling Morningstar:
- Totale activa: 346M
AXA Framlington Biotech Fund GBP Z Acc
5,177
+0,040
+0,82%
- Overzicht
- Profiel
- Historische Data
- Participaties
0P0000XMRD Overzicht
Op deze pagina vindt u een uitgebreid profiel van Axa Framlington Biotech Fund - R Accumulation. Kom meer te weten over onder meer het senior management, de totale activa, de investeringsstrategie en de contactgegevens van 0P0000XMRD.
Contact Informatie
Adres
100, Esplanade du Général de Gaulle
Paris, 92932
France
Paris, 92932
France
Telefoon
+33 1 44 45 70 00
Fax
Paris
Topmanagers
| Naam | Titel | Sinds | Tot |
|---|---|---|---|
| Cinney Zhang | - | 2023 | now |
| Linden Thomson | - | 2012 | now |
| Peter Hughes | Portfolio Manager | 2001 | 2023 |
| Biografie | Peter joined Redwheel in July 2023 as a Partner and Portfolio Manager. He will manage the Redwheel Life Changing Treatments strategy. His ambition for the role is to focus on improving patients’ lives, regardless of where they live by investing in companies facilitating improved health care outcomes while providing long-term capital appreciation for investors. Before Redwheel, Peter was Portfolio Manager of the AXA World Funds Longevity Economy fund and AXA Framlington Health fund, specialising in healthcare. Before this, he held appointments at Architas, in roles covering investment research and relationship management. Peter holds a PhD in biochemistry from University College London. He has a master's degree in chemistry from the University of Surrey and is a CFA Charterholder. He is also an ambassador for the Royal Marsden Cancer Charity. Peter was named as a 2021 Rising Star of Asset Management by Financial News. | ||
| Dani Saurymper | - | 2015 | 2020 |
| Biografie | Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare. | ||
| Gemma Game | - | 2011 | 2015 |
| Deane Donnigan | clinical Specialist | 2010 | 2011 |
| Biografie | Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen. | ||
| Andy Smith | Portfolio manager | 2009 | 2010 |
| Biografie | Andy joined AXA Framlington in April 2008 as Portfolio Manager within the healthcare team with specific responsibility for the AXA Framlington Biotech Fund. Previously, he spent three years at SV Life Sciences where he was responsible for managing a global biotechnology investment fund. From 2004 to 2005 he worked at Schroders as Director and Fund Manager, Global Equities. Between 2002 and 2004 he worked within the Asset Management division of the 3i Group as Investment Manager and then Director. | ||
| Deane Donnigan | clinical Specialist | 2007 | 2009 |
| Biografie | Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen. | ||
| Gareth Powell | Portfolio Manager | 2004 | 2007 |
| Biografie | Gareth Powell joined Polar Capital in 2007 to establish the healthcare investment team. He is joint manager of the Healthcare Opportunities Fund. He joined Framlington in 1999, later becoming a portfolio manager on the Framlington Health Fund. In 2002, Gareth helped launch the Framlington Biotech Fund, which he managed until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder. | ||
| Antony Milford | - | 2001 | 2007 |
Laat weten wat u vindt van Axa Framlington Biotech Fund - R Accumulation
Weet u zeker dat u deze grafiek wilt verwijderen?
Verwijderen Annuleren
Vervang de toegevoegde grafiek met een nieuwe grafiek?
Vervang Annuleren
Richtlijnen voor commentaar
Voeg Grafiek toe aan Commentaar
Blokkering bevestigen
Weet u zeker dat u %USER_NAME% wilt blokkeren?
Als u dit doet, kunnen u en %USER_NAME% geen publicaties meer van elkaar zien op Investing.com.
%USER_NAME% is toegevoegd aan uw lijst met geblokkeerde personen
Omdat u de blokkering van deze persoon net hebt opgeheven, moet u 48 uur wachten om hem/haar weer te kunnen blokkeren.
Rapporteer dit commentaar
Ik vind dit commentaar
Commentaar gemarkeerd
Bedankt!
Uw bericht is ter beoordeling verstuurd naar de moderatoren